RxDoctor Payments Data

Gerard Lippert, MD

Psychiatry · Ithaca, NYNPI 1013955152

Payments from drug & device makers

$31,327in general payments, 2019–2025

Across 187 payments — averaging $167.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$24K
  • Sunovion Pharmaceuticals Inc.$4K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$644
  • Neurocrine Biosciences, Inc.$263
  • Johnson & Johnson$261
  • plus $185 from 4 others

What the payments were for

  • Speaking & faculty fees$26,38884%
  • Food & beverage$4,88516%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,327 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$15,782
Medicare patients
82
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$117,906
Abilify MaintenaAripiprazole16$44,475
VraylarCariprazine Hcl26$35,240
Lurasidone Hcl54$23,092
RexultiBrexpiprazole14$20,268
Aripiprazole79$13,774
TrintellixVortioxetine Hydrobromide24$12,178
Clozapine161$9,384
Divalproex Sodium ErDivalproex Sodium35$3,715
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$2,987
Vilazodone Hcl12$2,619
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$2,485
Paliperidone ErPaliperidone24$2,119
Olanzapine86$2,024
Quetiapine Fumarate100$2,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$261$117,90635 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$644$64,74330 claims
AbbVieVraylar$1,298$35,24026 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$21$12,17824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →